Although we demonstrate that the antifibrotic effects of SDC2 in vivo are associated with decreased PAD2 expression in the lung, an important consideration is that there is limited evidence that PAD2 is directly involved in the development of pulmonary fibrosis in our model. The gene discussed is SDC2; the disease is pulmonary fibrosis.